HLVX (HilleVax) Net Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is HilleVax Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. HilleVax's Net Income for the three months ended in Sep. 2024 was $-25.82 Mil. HilleVax's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, HilleVax's net margin for the quarter that ended in Sep. 2024 was 0.00%.

The historical rank and industry rank for HilleVax's Net Margin % or its related term are showing as below:

HLVX's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -132.42
* Ranked among companies with meaningful Net Margin % only.

HilleVax Net Margin % Historical Data

The historical data trend for HilleVax's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HilleVax Net Margin % Chart

HilleVax Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Margin %

HilleVax Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Margin %	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of HilleVax's Net Margin %

For the Biotechnology subindustry, HilleVax's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HilleVax's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HilleVax's Net Margin % distribution charts can be found below:

* The bar in red indicates where HilleVax's Net Margin % falls into.

Save Embed

;

Save Embed

;

HilleVax Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

HilleVax's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-123.566	/	0
	=	%

HilleVax's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin	=	Net Income (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-25.823	/	0
	=	%

HilleVax (NAS:HLVX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

HilleVax Net Margin % Related Terms

Thank you for viewing the detailed overview of HilleVax's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

HilleVax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HilleVax Inc (NAS:HLVX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Harrison Avenue, Boston, MA, USA, 02118

Website

https://www.hillevax.com

HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Executives

Robert Hershberg	director, officer: President and CEO	3005 FIRST AVENUE, SEATTLE WA 98121
Shane Maltbie	officer: Chief Financial Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Aditya Kohli	director, officer: Chief Operating Officer	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Frazier Life Sciences X, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Astrid Borkowski	officer: Chief Medical Officer	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Nanette Cocero	director	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100, BOSTON MA 02109
Fhmls X, L.l.c.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Gary Dubin	director	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Jaime Sepulveda	director	C/O HILLEVAX INC., 75 STATE STREET 100 - #9995, BOSTON MA 02109
Takeda Vaccines, Inc.	10 percent owner	75 SIDNEY STREET, CAMBRIDGE MA 02139
Shelley Chu	director	ONE WINTHROP SQUARE, SUITE 400, BOSTON MA 02110
Susan Michele Silbermann	director	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Fhmls X, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Julie L. Gerberding	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David A Socks	officer: CFO & Chief Business Officer	C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130